2018
Risk factors for pleural effusion recurrence in patients with malignancy
Grosu HB, Molina S, Casal R, Song J, Li L, Diaz‐Mendoza J, Reddy C, Yarmus L, Schiavo D, Simoff M, Johnstun J, Raid A, Feller‐Kopman D, Lee H, Sahetya S, Foley F, Maldonado F, Tian X, Noor L, Miller R, Mudambi L, Saettele T, Vial‐Rodriguez M, Eapen GA, Ost DE. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology 2018, 24: 76-82. PMID: 29966171, PMCID: PMC7315912, DOI: 10.1111/resp.13362.Peer-Reviewed Original ResearchConceptsMalignant pleural effusionRisk factorsFluid recurrenceMetastatic diseasePleural fluidHazards modelRecurrent symptomatic malignant pleural effusionsSymptomatic malignant pleural effusionRetrospective multicentre cohort studyFine-Gray subdistribution hazard modelPleural effusion recurrenceMulticentre cohort studyHazard of recurrenceCause-specific hazards modelPleural fluid cytologyChest X-rayPleural fluid LDHPleural effusion sizeSubdistribution hazard modelEffusion recurrenceFirst thoracentesisSymptom palliationCohort studyCumulative incidencePrimary outcome
2007
Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. CardioVascular And Interventional Radiology 2007, 31: 299-307. PMID: 17922160, DOI: 10.1007/s00270-007-9186-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalHepatic arterial embolizationGastrointestinal stromal tumorsOverall survivalNeuroendocrine tumorsRadiologic responseArterial embolizationDisease stabilizationLiver involvementLiver metastasesMajor complicationsLonger progression-free survivalLiver tumor burdenMedian overall survivalMetastatic neuroendocrine tumorsProcedure-related mortalityMajority of patientsManagement of patientsAdditional risk factorsHigh response rateStable diseaseSymptom palliationPartial responsePerformance statusProgressive disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply